A detailed history of Wells Fargo & Company transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 395,297 shares of ALDX stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
395,297
Previous 387,304 2.06%
Holding current value
$2.05 Million
Previous $1.27 Million 3.32%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.25 - $4.72 $25,977 - $37,726
7,993 Added 2.06%
395,297 $1.31 Million
Q1 2024

May 10, 2024

BUY
$2.77 - $4.22 $116,869 - $178,046
42,191 Added 12.23%
387,304 $1.27 Million
Q4 2023

Feb 09, 2024

BUY
$1.47 - $6.06 $2,706 - $11,156
1,841 Added 0.54%
345,113 $1.21 Million
Q3 2023

Nov 13, 2023

BUY
$6.11 - $8.16 $20,749 - $27,711
3,396 Added 1.0%
343,272 $2.29 Million
Q2 2023

Aug 15, 2023

BUY
$7.11 - $11.89 $483,714 - $808,912
68,033 Added 25.03%
339,876 $2.85 Million
Q1 2023

May 12, 2023

SELL
$5.77 - $9.93 $265,443 - $456,819
-46,004 Reduced 14.47%
271,843 $2.7 Million
Q4 2022

Feb 13, 2023

BUY
$5.08 - $7.09 $37,800 - $52,756
7,441 Added 2.4%
317,847 $2.21 Million
Q3 2022

Nov 14, 2022

SELL
$3.8 - $7.74 $79,613 - $162,160
-20,951 Reduced 6.32%
310,406 $1.66 Million
Q2 2022

Aug 12, 2022

BUY
$2.43 - $4.85 $1,992 - $3,976
820 Added 0.25%
331,357 $1.32 Million
Q1 2022

May 16, 2022

BUY
$3.25 - $5.17 $305,165 - $485,447
93,897 Added 39.68%
330,537 $1.47 Million
Q4 2021

Feb 14, 2022

SELL
$3.5 - $9.63 $79,873 - $219,766
-22,821 Reduced 8.8%
236,640 $947,000
Q3 2021

Nov 15, 2021

BUY
$7.94 - $11.31 $941,946 - $1.34 Million
118,633 Added 84.24%
259,461 $2.28 Million
Q2 2021

Aug 16, 2021

BUY
$10.44 - $14.85 $690,626 - $982,357
66,152 Added 88.59%
140,828 $1.6 Million
Q1 2021

May 13, 2021

BUY
$6.53 - $14.42 $440,272 - $972,239
67,423 Added 929.59%
74,676 $887,000
Q4 2020

Feb 09, 2021

BUY
$6.31 - $8.13 $44,270 - $57,040
7,016 Added 2960.34%
7,253 $50,000
Q3 2020

Nov 05, 2020

SELL
$4.0 - $7.53 $1,112 - $2,093
-278 Reduced 53.98%
237 $2,000
Q2 2020

Aug 13, 2020

SELL
$1.97 - $5.05 $31,984 - $81,991
-16,236 Reduced 96.93%
515 $2,000
Q1 2020

May 14, 2020

BUY
$1.62 - $6.4 $27,136 - $107,206
16,751 New
16,751 $41,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $302M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.